Helping Sanofi understand what is driving impact, what is limiting it, and how the Respiratory Vision can stay clear, credible, and usable across Asthma, COPD, and priority markets — including the US, Germany, and Japan.
Can the Respiratory Vision hold as a simple, repeatable strategic core — while giving Asthma, COPD, and priority markets the flex they need?
Sanofi is building a refreshed Respiratory Vision supported by Asthma and COPD agendas. At the same time, competitors are already trying to shape how Respiratory is understood — through mechanism stories, convenience stories, broad biology stories, and disease-specific claims.
The challenge is not simply to create a strong Vision. It is to make sure the Vision can stay simple, credible, and actionable as it moves across disease areas, markets, competitor pressure, and future HCP-facing communication.
TSLP / IL-33, epithelial health, mucus biology, clinical remission, broad efficacy, and upper / lower airway connection.
RiskCan make the future of Respiratory feel upstream, even before proof is fully settled.
IL-5 continuity, Nucala / Exdensur, dosing convenience, hospitalisation, disease stability, and early treatment cues.
RiskCan make the decision feel easy, even if the story is narrower.
Proven Type 2 science, broad respiratory evidence, patient impact, and clinical action across Asthma and COPD.
OpportunityDefine the organising idea of Respiratory.
The space where science, patient value, and trusted clinical action come together as one Respiratory Vision.
Working hypothesis based on current CI; to be validated through research.